MedWorm: Buspirone

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 01 Feb 2012 05:00:00 +0100

Updated Date: Feb 1, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Visual social preferences of lone zebrafish in a novel environment: strain and anxiolytic effects

Genes, Brain and Behavior — Tue, 31 Jan 2012 05:00:00 +0100

We examined the effects of the cannabinoid receptor agonist WIN55,212‐2 (1 mg/L), or 5‐HT1A agonist buspirone (10 mg/L) on Petco short‐fin social choice. Fish were bath‐exposed to test compounds for 10 min, under these conditions [3H]CP55,940 (4 nM) bound to brain with a concentration of 1.9‐6.4 fmol/mg 5‐30 min afterward. Social approach was measured 20 min following acclimation to the testing arena. WIN55,212‐2 and buspirone increased short‐fin dwelling near boxed zebrafish. In zebrafish whole brain homogenates, buspirone displaced [3H]8‐OH‐DPAT (dissociation constant, KD = 16 +1.2 nM) with an inhibition constant (Ki) of 1.8+1.0 nM lower than that of WAY100,635 (Ki ∼1000 nM). These fish social choice tests may enhance social behavior research, and are useful for stu...

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [American Health Packaging]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 Jan 2012 05:00:00 +0100

Updated Date: Jan 13, 2012 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Interaction of estrogen with central serotonergic mechanisms in human sensory processing: loudness dependence of the auditory evoked potential and mismatch negativity

Journal of Psychopharmacology — Tue, 10 Jan 2012 05:00:00 +0100

We examined the effects of estrogen pre-treatment on modulation of loudness dependence of the auditory evoked potential (LDAEP) and mismatch negativity by the 5-HT1A receptor partial agonist, buspirone. Using a double-blind, placebo-controlled, repeated-measures design in healthy female volunteers, we observed that buspirone treatment significantly increased LDAEP slope. Estrogen increased LDAEP slope on its own, and a further LDAEP increase by buspirone was not seen after estrogen pre-treatment. Similar results were observed for mismatch negativity, where buspirone caused a small increase of latency, although not amplitude, after placebo but not estrogen pre-treatment, which enhanced mismatch negativity latency on its own. These results are in line with our previous findings on prepulse i...

The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats

Psychopharmacology — Fri, 06 Jan 2012 16:49:30 +0100

Conclusions These results indicate that 5-HT1A agonism is adequate to ameliorate the PCP-induced impairment in NOR and suggest further study of utilizing the combination of a 5-HT1A agonist and an atypical APD to ameliorate some types of cognitive impairment in schizophrenia. Content Type Journal ArticleCategory Original InvestigationPages 1-11DOI 10.1007/s00213-011-2561-4Authors M. Horiguchi, Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USAH. Y. Meltzer, Division of Psychopharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USA Journal PsychopharmacologyOnline ISSN 1432-2072Print ISSN 0033-3158 (Source: Psychopharmacology)

Buspirone for Bruxism in a Child with Pervasive Developmental Disorder-Not Otherwise Specified

Journal of Child and Adolescent Psychopharmacology — Fri, 23 Dec 2011 14:09:29 +0100

Journal of Child and Adolescent Psychopharmacology Dec 2011, Vol. 21, No. 6: 643-645. (Source: Journal of Child and Adolescent Psychopharmacology)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Interventions for treating anxiety after stroke.

Cochrane Database of Systematic Reviews — Tue, 20 Dec 2011 01:00:04 +0100

CONCLUSIONS: There is insufficient evidence to guide the treatment of anxiety after stroke. The data available suggest that pharmaceutical therapy (paroxetine and buspirone) may be effective in reducing anxiety symptoms in stroke patients with co-morbid anxiety and depression. No information was available for stroke patients with anxiety only. Randomised placebo controlled trials are needed. PMID: 22161439 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

BUSPIRONE HYDROCHLORIDEtablet [H.J. Harkins Company, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 05 Dec 2011 05:00:00 +0100

Updated Date: Dec 5, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Buspirone for Bruxism in a Child with Pervasive Developmental Disorder-Not Otherwise Specified

Journal of Child and Adolescent Psychopharmacology — Sat, 03 Dec 2011 04:05:02 +0100

Journal of Child and Adolescent Psychopharmacology , Vol. 0, No. 0. (Source: Journal of Child and Adolescent Psychopharmacology)

Psychotherapeutic and Pharmacologic Treatment of Schizotypal Personality Disorder: The Heuristic Utility of Stressing Function Over Form

Clinical Case Studies — Thu, 01 Dec 2011 05:00:00 +0100

Although the traditional emphasis on overt symptomatology leads readily to diagnosis, such categorization typically assumes a pathological process within the individual that may at best be managed or modified. Conceptualization of symptoms in terms of adaptive and functional considerations may facilitate and broaden options for treatment, potentially improving outcome. This case study provides an example of treatment of schizotypal personality disorder using such an approach. Psychotherapy and medication were directed toward alleviating symptoms of anxiety and depression producing functional impairment in memory, and development of interpersonal skills to increase prospects for reinforcement in interaction with others was implemented to decrease the need for fantasy as a means of obtaining...

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 22 Nov 2011 05:00:00 +0100

Updated Date: Nov 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPIRONE HYDROCHLORIDEtablet [Lake Erie Medical DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 16 Nov 2011 05:00:00 +0100

Updated Date: Nov 16, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 14 Nov 2011 05:00:00 +0100

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [PD-Rx Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 14 Nov 2011 05:00:00 +0100

Updated Date: Nov 14, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial

Acta Psychiatrica Scandinavica — Sat, 12 Nov 2011 05:00:00 +0100

Conclusion: In all domains of the pharmacopsychometric triangle, bupropion‐SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram. (Source: Acta Psychiatrica Scandinavica)

Effect of buspirone, a 5‐HT1A receptor agonist, on esophageal motility in healthy volunteers

Diseases of the Esophagus — Wed, 02 Nov 2011 04:00:00 +0100

SUMMARYThere are limited data concerning the effects of 5‐HT1A receptor activation on esophageal motility. Sumatriptan, a 5‐HT1A receptor agonist, was recently reported to enhance esophageal peristalsis after intravenous administration. Buspirone, an orally available 5‐HT1A receptor agonist, was shown to modulate gastroduodenal motor function. Our aim was to evaluate the effect of buspirone on esophageal motility of healthy volunteers. On two separate visits, 20 healthy volunteers aged 21–29 years (nine women) underwent esophageal manometry before and 10, 30, and 60 minutes after the administration of buspirone 20‐mg or placebo capsule, according to a double‐blind crossover design. At each time point, we compared buspirone and placebo effects on: resting pressure of the lower e...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Quantitative estimation of circulating metabolites without synthetic standards by ultra-high-performance liquid chromatography/high resolution accurate mass spectrometry in combination with UV correction.

Rapid Communications in Mass Spectrometry : RCM — Sun, 23 Oct 2011 13:25:42 +0100

We present here an approach to determine the extent of circulating metabolites using 'metabolite standards' generated by in vitro incubations in combination with the correction for mass spectrometry response based on UV response. The study was done by coupling ultra-high-performance liquid chromatography (UHPLC) to LTQ-Orbitrap high-resolution mass spectrometry, and the quantitation was based on full scan high-resolution accurate mass analysis in combination with retention time. First, we investigated the separation capacity of a 10.5 min UHPLC method and the quantitative capability of an LTQ-Orbitrap for full scan accurate mass quantitation by spiking chemical standards of buspirone and its six metabolites in blank plasma. Then we demonstrated the use of a UV correction approach to quan...

Surface cooling for induction of mild hypothermia in conscious healthy volunteers - a feasibility trial

BioMed Central — Sat, 22 Oct 2011 04:00:00 +0100

Conclusions: Cooling to body temperature below 35degreesC by the use of a non invasive surface cooling is feasible and safe in conscious healthy volunteers. Further studies are needed to investigate an altered cooling protocol to achieve temperatures below 35degreesC. (Source: BioMed Central)

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 13 Oct 2011 05:00:00 +0100

Updated Date: Oct 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 11 Oct 2011 05:00:00 +0100

Updated Date: Oct 11, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Menstrual cycle‐dependent febrile episode mediated by sequence‐specific repression of poly(ADP‐ribose) polymerase‐1 on the transcription of the human serotonin receptor 1A gene

Human Mutation — Tue, 11 Oct 2011 04:00:00 +0100

AbstractThe Serotonin receptor 1A (encoded by the HTR1A gene) plays a critical role in serotonergic transmission and was linked with many human diseases. A 33‐year‐old woman with rare menstrual cycle‐dependent fever showed abnormal estrogen profile and responded well to the HTR1A agonist buspirone, suggesting that her fevers were allied to estrogen‐related HTR1A deficiency. We identified an adenine deletion 480‐bases upstream of the translation start site (i.e., ‐480delA) of HTR1A in this patient. To determine the underlying mechanism of ‐480delA‐mediated HTR1A deficiency, we first showed that HTR1A ‐480‐region can be bound by multiple nuclear protein(s). We then identified poly (ADP‐ribose) polymerase (PARP1) as one of the proteins that binds to HTR1A ‐480‐region...

MedWorm Sponsor Message: Find the best January Sales in the UK.

An Efficient Synthesis of Aripiprazole, Buspirone and NAN‐190 by the Reductive Alkylation of Amines Procedure

Archiv der Pharmazie — Wed, 05 Oct 2011 04:00:00 +0100

AbstractThe reductive alkylation of amines procedure was applied for the synthesis of aripiprazole 1a, buspirone 1b, and NAN‐190 1c.The reductive alkylation of amines procedure has been applied for the synthesis of aripiprazole 1a, buspirone 1b, and NAN‐190 1c. (Source: Archiv der Pharmazie)

Validated RP-HPLC Method for the Determination of Buspirone in Pharmaceutical Formulations

Clinical and Developmental Immunology — Wed, 28 Sep 2011 22:55:08 +0100

A simple, selective, linear, precise, and accurate RP-HPLC method was developed and validated for the rapid assay of the Buspirone in tablet dosage form. Isocratic elution at a flow rate of 1.0 mL/min was employed on a symmetry C18 (250×4.6 mm, 5 μm in particle size) at ambient temperature. The mobile phase consisted of water : acetonitrile : methanol 45 : 35 : 20(V/V). The UV detection wavelength was 210 nm, and 20 μL sample was injected. The retention time for the Buspirone was 7.057 min. The percentage RSD for precision and accuracy of the method was found to be less than 2%. The method was validated as per the ICH guidelines. The method can be successfully applied for ...

Psychopharmacological Neuroprotection in Neurodegenerative Diseases, Part III: Criteria-Based Assessment: A Report of the ANPA Committee on Research [SPECIAL ARTICLES]

J Neuropsychiatry Clin Neurosci — Fri, 23 Sep 2011 04:00:00 +0100

This report identifies FDA-approved, first-line psychotropic drugs affecting intracellular mechanisms and meriting disease-modifying clinical trials in NDDs. The authors evaluated evidence for neuroprotection according to 1) preclinical; and 2) clinical criteria. Despite low-to-moderate preclinical evidence scores and scant clinical evidence, the most promising investigative priorities are 1) lithium and paroxetine in Alzheimer's disease (AD); 2) lithium in tauopathies (frontotemporal lobar degeneration [FTLD], FTDP-17); 3) lithium-plus-valproate in AD and amyotrophic lateral sclerosis; 4) pramipexole and valproate in Parkinson's disease; 5) amantadine and buspirone in multiple system atrophy; and 6) antidepressants in Huntington's disease. Preliminary clinical results signal caution regar...

Buspirone before prenatal stress protects against adverse effects of stress on emotional and inflammatory pain-related behaviors in infant rats: Age and sex differences.

Brain Research — Fri, 02 Sep 2011 04:00:00 +0100

Authors: Butkevich IP, Mikhailenko VA, Vershinina EA, Otellin VA, Aloisi AM Abstract Prenatal stress strengthens tonic pain and provokes depression. The serotoninergic system is involved in these processes. We recently showed that maternal buspirone, a 5-HT1A receptor agonist, protects against the adverse effects of in utero stress on depression and pain in adult rat offspring. Using a similar maternal treatment with buspirone, we focus here on the infant stage, which is important for the correction of prenatal abnormalities. Maternal buspirone before restraint stress during the last week of pregnancy decreased the time of immobility in the forced swim test in the infant offspring. Prenatal stress increased formalin-induced pain in the second part of the time-course of the response...

Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second‐line medication strategies for treating depression?

Depression and Anxiety — Thu, 01 Sep 2011 23:00:00 +0100

Conclusions: Remission and response rates following initial antidepressant treatment failure did not differ by treatment strategy for patients with coexisting atypical symptoms or insomnia. However, some second‐step treatments for depression may be more effective than others in the presence of coexisting low energy. Subsequent prospective testing is necessary to confirm these initial findings. Depression and Anxiety 0:1–10, 2011. © 2011 Wiley‐Liss, Inc. (Source: Depression and Anxiety)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

T134 formalin-induced pain and corticosterone stress responses in prenatally stressed infant male rats: effects of maternal buspirone during pregnancy

European Journal of Pain Supplements — Thu, 01 Sep 2011 04:00:00 +0100

(Source: European Journal of Pain Supplements)

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 24 Aug 2011 05:00:00 +0100

Updated Date: Aug 24, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [PD-Rx Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 08 Aug 2011 05:00:00 +0100

Updated Date: Aug 8, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Buspirone/duloxetine/lorazepam/sulpiride overdose: Bezoar formation leading to esophageal obstruction (first report for sulpiride, buspirone and duloxetine): case report

Reactions — Mon, 01 Aug 2011 15:09:42 +0100

(Source: Reactions)

BUSPIRONE HYDROCHLORIDEtablet [Teva Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 20 Jul 2011 05:00:00 +0100

Updated Date: Jul 20, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPIRONE HYDROCHLORIDEtablet [Preferred Pharmaceuticals, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 01 Jul 2011 05:00:00 +0100

Updated Date: Jul 1, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Buspirone improves the anti-cataleptic effect of levodopa in 6-hydroxydopamine-lesioned rats.

Pharmacological Reports — Fri, 01 Jul 2011 04:00:00 +0100

Authors: Mahmoudi J, Nayebi AM, Samini M, Reyhani-Rad S, Babapour V Abstract In Parkinson's disease (PD), prolonged exposure to L-3,4-dihydroxyphenylalanine (L-DOPA) results in motor fluctuations, such as the on-off phenomenon, and L-DOPA-induced dyskinesia. Previously, we found that activation of 5-HT(1A) in the substantia nigra pars compacta (SNc) decreased catalepsy in parkinsonian rats. In the current investigation, we attempted to evaluate the effect of buspirone on the anti-cataleptic effect of L-DOPA in 6-hydroxydopamine (6-OHDA)-lesioned male Wistar rats. Catalepsy was induced by the unilateral infusion of 6-OHDA (8 μg/2 μl/rat) into the central region of the SNc. After a 3-week recovery period, rats received L-DOPA intraperitoneally (ip; 15 mg/kg) twice daily for 20 days...

BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 30 Jun 2011 05:00:00 +0100

Updated Date: Jun 30, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [American Health Packaging]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 27 Jun 2011 05:00:00 +0100

Updated Date: Jun 27, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [UDL Laboratories, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 22 Jun 2011 05:00:00 +0100

Updated Date: Jun 22, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Bryant Ranch Prepack]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDE (Buspirone Hydrochloride) Tablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Jun 2011 05:00:00 +0100

Updated Date: Jun 15, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 13 Jun 2011 05:00:00 +0100

Updated Date: Jun 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 09 Jun 2011 05:00:00 +0100

Updated Date: Jun 9, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 25 May 2011 05:00:00 +0100

Updated Date: May 25, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [STAT RX USA LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 20 May 2011 05:00:00 +0100

Updated Date: May 20, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 13 May 2011 05:00:00 +0100

Updated Date: May 13, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPIRONE HYDROCHLORIDEtablet [Cardinal Health]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 06 May 2011 05:00:00 +0100

Updated Date: May 6, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Effect of Experimental Temperature on the Permeation of Model Diffusants Across Porcine Buccal Mucosa.

AAPS PharmSciTech — Tue, 03 May 2011 23:00:00 +0100

Authors: Kulkarni UD, Mahalingam R, Li X, Pather I, Jasti B The influence of experimental temperature on the permeability of model diffusants across porcine buccal mucosa was investigated in vitro. The permeability increased significantly as the experimental temperature was increased in increments of approximately 7°C. It was observed that the apparent permeability and temperature were related by an exponential relationship that conformed to the Arrhenius equation. Diffusants with higher lipophilicities-buspirone and bupivacaine-had lower activation energies for diffusion when compared to hydrophilic diffusants-antipyrine and caffeine. The activation energy for diffusion of the model diffusants decreased linearly with increasing distribution coefficients across porcine buccal mucosa. ...

BUSPIRONE HYDROCHLORIDEtablet [NCS HealthCare Of KY, Inc Dba Vangard Labs]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 02 May 2011 05:00:00 +0100

Updated Date: May 2, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDE (Buspirone Hydrochloride) Tablet [Preferred Pharmaceuticals, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 28 Apr 2011 05:00:00 +0100

Updated Date: Apr 28, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Pharmacological Treatment of Cannabis Dependence.

Current Pharmaceutical Design — Wed, 27 Apr 2011 23:00:00 +0100

Authors: Weinstein AM, Gorelick DA Cannabis is the most frequently used illegal psychoactive substance in the world. There is a significant increase in the number of treatment admissions for cannabis use disorders in the past few years, and the majority of cannabis-dependent individuals who enter treatment have difficulty in achieving and maintaining abstinence. Thus, there isincreased need for medications that can be used to treat this population. So far, no medication has been shown broadly and consistently effective; none has been approved by any national regulatory authority. Medications studied have included those that alleviate symptoms of cannabis withdrawal (e.g., dysphoric mood, irritability),those that directly affect endogenous cannabinoid receptor function, and those that h...

Agonists at the Serotonin Receptor (5-HT1A) Protect the Retina from Severe Photo-Oxidative Stress [Retinal Cell Biology]

Investigative Ophthalmology — Sun, 03 Apr 2011 23:00:00 +0100

Conclusions. 5-HT1A agonists provided potent and complete functional and structural protection. Protection was inhibited by treatment with WAY-100635, confirming the requirement for activating the 5-HT1A receptor in initiating this survival pathway. Single-dose experiments with AL-8309A suggest that the mechanism of protection is rapidly activated and protection persists for 48 hours. AL-8309B (1.75%) was effective after topical ocular dosing. AL-8309B is under evaluation in the clinic and may be useful in treating age-related macular degeneration. (Source: Investigative Ophthalmology)

Simultaneous quantification of loureirin A and loureirin B in rat urine, feces, and bile by HPLC-MS/MS method and its application to excretion study.

Analytical and Bioanalytical Chemistry — Thu, 24 Mar 2011 00:00:00 +0100

Authors: Zhang Y, Li Y, Chen B, Deng Y, Li Y A simple HPLC-MS/MS method for simultaneous determination of loureirin A and loureirin B in rat urine, feces, and bile after oral administration of 10.6 g/kg of longxuejie (one rare traditional Chinese medicinal herb) was developed for the first time. The analytes and buspirone (internal standard) were separated on a C(5) column with acetonitrile-water (containing 0.1% formic acid) as mobile phase at a flow rate of 0.4 min/mL. The detector was a Q-trap™ mass spectrometer with an electrospray ionization interface operating in the multiple reaction monitoring mode. Calibration curves of loureirin A in rat urine, feces, and bile were linear over the concentration range of 1.00-5,000 ng/mL. Loureirin B in rat urine, feces, and bile ranged b...

5-HT(1A)-receptor over-expressing mice: Genotype and sex dependent responses to antidepressants in the forced swim-test.

Neuropharmacology — Wed, 23 Mar 2011 00:00:00 +0100

In this study we examined the impact of postsynaptic 5-HT(1A)-receptor over-expression in corticolimbic areas of male and female mice on the performance in the forced swim-test (FST). Furthermore, we investigated their response to the serotonin selective reuptake inhibitor (SSRI) citalopram in comparison to the selective noradrenaline reuptake inhibitor reboxetine, as well as the partial 5-HT(1A)-receptor agonists, buspirone and S 15535. Additionally, these drugs were evaluated in the open field-test in order to observe effects on motor activity. The density of 5-HT(1A)-receptors in discrete corticolimbic regions was determined in detail by quantitative autoradiography with [(3)H]8-OH-DPAT to investigate genotype as well as sex dependent differences in the expression pattern. [(3)H]8-OH-DP...

Patterns of avoidance behaviours in the light/dark preference test in young juvenile zebrafish: A pharmacological study.

Behavioural Brain Research — Mon, 21 Mar 2011 00:00:00 +0100

We report that juveniles display strong dark-avoidance behaviours in this test. Specifically, juveniles spent significantly less time, displayed high latency to enter and moved significantly less in the dark compartment relative to the white compartment of the testing apparatus. The expression of these dark-avoidance behaviours was significantly attenuated and increased by commonly used anxiolytic (diazepam, buspirone, ethanol) and anxiogenic (caffeine but not FG-7142) drugs, respectively. We also show that the expression of dark-avoidance behaviours can be significantly reduced in a manner similar to what is achieved with anxiolytic drugs, simply by decreasing the contrast between the white and dark zones, which made the dark zone less dark. Taken together, these findings provide the firs...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Alprazolam/buspirone/mirtazapine overdose: Sedation, atelectasis and QT prolongation: case report

Reactions — Sun, 06 Mar 2011 17:02:10 +0100

(Source: Reactions)

Effects on Locomotion, Muscle, Bone, and Blood Induced by a Combination Therapy Eliciting Weight-Bearing Stepping in Nonassisted Spinal Cord-Transected Mice

Neurorehabilitation and Neural Repair — Fri, 25 Feb 2011 00:00:00 +0100

Conclusion. Although translation of these findings needs further experimentation, similar pharmacological activation of the CPG offers a novel therapeutic target to provide some health benefits in motor-complete SCI patients. (Source: Neurorehabilitation and Neural Repair)

Application of a Fluorescence-Based Continuous-Flow Bioassay to Screen for Diversity of Cytochrome P450 BM3 Mutant Libraries

Journal of Biomolecular Screening — Fri, 04 Feb 2011 00:00:00 +0100

In conclusion, the developed FIA EAD approach is suitable to screen for diversity within BM3 mutants and this alternative screening technology offers new perspectives for rapid and sensitive screening of compound libraries towards BM3 mutants. (Source: Journal of Biomolecular Screening)

Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease

Journal of Neural Transmission — Thu, 27 Jan 2011 17:37:21 +0100

Abstract A central problem in the treatment of Parkinson’s disease (PD) is the development of motor disturbances like l-DOPA-induced dyskinesia (LID) after long-term treatment. Preclinical and clinical studies demonstrated that serotonin 5-HT1A receptor agonists attenuate this disabling motor side effect. The aim of this study was to investigate the ability of flibanserin compared to buspirone to attenuate l-DOPA-sensitized contraversive circling in hemiparkinsonian rats, which is an animal model of LID. Both drugs have a preferential affinity for the serotonin 5-HT1A receptors. Buspirone was in comparison because it was expected to have an effect in this model. Unilaterally 6-hydroxydopamine lesioned rats were treated twice daily intraperitoneally (ip) with l-DOPA methyles...

The Use of Monoamine Pharmacological Agents in the Treatment of Sexual Dysfunction: Evidence in the Literature

The Journal of Sexual Medicine — Thu, 27 Jan 2011 00:00:00 +0100

Conclusion. There has been tremendous progress over the past 50 years in understanding the role of monoamines in sexual function and the effect of pharmacologic agents which stimulate or antagonize monoaminergic receptors on sexual dysfunction. Nevertheless, large, double‐blind, placebo‐controlled studies evaluating the efficacy of currently available agents in populations without comorbid disorders are limited, preventing adequate interpretation of data. Continued research on sexual function and specific receptor subtypes will result in the development of more selective pharmacologic agents with the goal of increasing efficacy without the dose‐limiting side effects of nonselective agents. Moll JL and Brown CS. Treatment of sexual dysfunction: Evidence in the literature. J Sex Med...

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPIRONE HYDROCHLORIDEtablet [TEVA Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 06 Jan 2011 05:00:00 +0100

Updated Date: Jan 6, 2011 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Advances in the Management of Treatment-Resistant Depression [CLINICAL SYNTHESIS]

FOCUS — Tue, 28 Dec 2010 00:00:00 +0100

Treatment-resistant depression (TRD) is a prevalent, disabling, and costly condition affecting 1%–4% of the U.S. population. Current approaches to managing TRD include medication augmentation (with lithium, thyroid hormone, buspirone, atypical antipsychotics, or various antidepressant medications), psychotherapy, and ECT. Advances in understanding the neurobiology of mood regulation and depression have led to a number of new potential approaches to managing TRD, including medications with novel mechanisms of action and focal brain stimulation techniques. This review will define and discuss the epidemiology of TRD, review the current approaches to its management, and then provide an overview of several developing interventions. (Source: FOCUS)

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 27 Dec 2010 05:00:00 +0100

Updated Date: Dec 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Metabolism of Benzodiazepine and Non-Benzodiazepine Anxiolytic-Hypnotic Drugs: An Analytical Point of View.

Current Drug Metabolism — Tue, 21 Dec 2010 00:00:00 +0100

Authors: Mandrioli R, Mercolini L, Raggi MA A review with 132 references. Several kinds of anxiolytic and hypnotic drugs are currently available on the market. Although BZDs are surely the most frequently prescribed among them, several chemically unrelated compounds have been commercialised, which can provide similar or even higher efficacy and tolerability. These drugs can prove useful for patients who are non-responder or intolerant to benzodiazepine treatment, thus giving broader therapeutic options to the clinician. The most important studies on the metabolic characteristics of several non-benzodiazepine anxiolytics and hypnotics are reported and briefly discussed in this review; moreover, the analytical methods related to these studies are also described and commented upon and the...

BUSPIRONE HYDROCHLORIDEtablet [Rebel Distributors Corp]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 20 Dec 2010 05:00:00 +0100

Updated Date: Dec 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPIRONE HYDROCHLORIDEtablet [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 20 Dec 2010 05:00:00 +0100

Updated Date: Dec 20, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Hydroxyzine for generalised anxiety disorder.

Cochrane Database of Systematic Reviews — Thu, 16 Dec 2010 07:30:21 +0100

Authors: Guaiana G, Barbui C, Cipriani A Generalised anxiety disorder (GAD) is a common chronic long-term psychiatric disorder, particularly frequent in primary care. There are several treatment options available, both non-pharmacological (i.e. cognitive behavioral therapy) and pharmacological. Among the pharmacological interventions, antidepressants, buspirone and benzodiazepines (BDZs) have been studied in GAD. Hydroxyzine is an anti-histamine medication which has been used in the treatment of anxiety. PMID: 21154375 [PubMed - in process] (Source: Cochrane Database of Systematic Reviews)

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 16 Dec 2010 05:00:00 +0100

Updated Date: Dec 16, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [Watson Laboratories, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 15 Dec 2010 05:00:00 +0100

Updated Date: Dec 15, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPIRONE HYDROCHLORIDEtablet [REMEDYREPACK INC. ]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 10 Dec 2010 05:00:00 +0100

Updated Date: Dec 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [Preferred Pharmaceuticals, Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 06 Dec 2010 05:00:00 +0100

Updated Date: Dec 6, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies.]

Revista Brasileira de Psiquiatria — Wed, 01 Dec 2010 00:00:00 +0100

CONCLUSION: Despite the therapeutic potential of medicinal plants in generalized anxiety disorder, very few controlled trials assessing herbal medicines in generalized anxiety disorder were found. Additionally, these studies present serious flaw design. PMID: 21308265 [PubMed - as supplied by publisher] (Source: Revista Brasileira de Psiquiatria)

BUSPIRONE HYDROCHLORIDEtablet [Lake Erie Medical DBA Quality Care Products LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 17 Nov 2010 05:00:00 +0100

Updated Date: Nov 17, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Density and Function of Central Serotonin (5‐HT) Transporters, 5‐HT1A and 5‐HT2A Receptors, and Effects of their Targeting on BTBR T+tf/J Mouse Social Behavior.

Journal of Neurochemistry — Thu, 11 Nov 2010 05:45:33 +0100

AbstractBTBR mice are potentially useful tools for autism research because their behavior parallels core social interaction impairments and restricted‐repetitive behaviors. Altered regulation of central serotonin (5‐HT) neurotransmission may underlie such behavioral deficits. To test this, we compared 5‐HT transporter (SERT), 5‐HT1A and 5‐HT2A receptor densities among BTBR and C57 strains. Autoradiographic [3H] cyanoimipramine (1nM) binding to SERT was 20‐30% lower throughout the adult BTBR brain as compared to C57BL/10J mice. In hippocampal membrane homogenates [3H] citalopram maximal binding (Bmax) to SERT was 95 + 13 fmol/mg protein in BTBR and 171 + 20 fmol/mg protein in C57BL/6J mice, and the BTBR dissociation constant (KD) was 2 + 0.3 nM vs. 1.1 + 0.2 in C57BL/6J mice. Hi...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPAR (Buspirone Hydrochloride) Tablet [Bristol-Myers Squibb Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 10 Nov 2010 05:00:00 +0100

Updated Date: Nov 10, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Density and function of central serotonin (5‐HT) transporters, 5‐HT1A and 5‐HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior

Journal of Neurochemistry — Wed, 10 Nov 2010 00:00:00 +0100

J. Neurochem. (2011) 10.1111/j.1471‐4159.2010.07104.xAbstractBTBR mice are potentially useful tools for autism research because their behavior parallels core social interaction impairments and restricted‐repetitive behaviors. Altered regulation of central serotonin (5‐HT) neurotransmission may underlie such behavioral deficits. To test this, we compared 5‐HT transporter (SERT), 5‐HT1A and 5‐HT2A receptor densities among BTBR and C57 strains. Autoradiographic [3H] cyanoimipramine (1nM) binding to SERT was 20–30% lower throughout the adult BTBR brain as compared to C57BL/10J mice. In hippocampal membrane homogenates, [3H] citalopram maximal binding (Bmax) to SERT was 95 ± 13 fmol/mg protein in BTBR and 171 ± 20 fmol/mg protein in C57BL/6J mice, and the BTBR dissociati...

BUSPAR (Buspirone Hydrochloride) Tablet [Bristol-Myers Squibb Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 15 Oct 2010 05:00:00 +0100

Updated Date: Oct 15, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

[Medicinal plants for the treatment of generalized anxiety disorder: a review of controlled clinical studies.]

Revista Brasileira de Psiquiatria — Thu, 14 Oct 2010 23:00:00 +0100

CONCLUSION: Despite the therapeutic potential of medicinal plants in generalized anxiety disorder, very few controlled trials assessing herbal medicines in generalized anxiety disorder were found. Additionally, these studies present serious flaw design. PMID: 20963375 [PubMed - as supplied by publisher] (Source: Revista Brasileira de Psiquiatria)

Antiarrhythmic, serotonin antagonist and antianxiety activities of novel substituted thiophene derivatives synthesized from 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide.

European Journal of Medicinal Chemistry — Tue, 12 Oct 2010 23:00:00 +0100

Authors: Amr AE, Sherif MH, Assy MG, Al-Omar MA, Ragab I A series of novel thiophene derivatives 3-17 were synthesized by initial reactions of 2-amino-4,5,6,7-tetrahydro-N-phenylbenzo[b]thiophene-3-carboxamide 1 and 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carbonitrile 7 with different organic reagents. The structures of newly synthesized compounds were confirmed by IR, (1)H NMR, MS spectral data and elemental analysis. Initially the acute toxicity of the compounds was assayed via the determination of their LD(50). All the compounds were screened for their antiarrhythmic, serotonin antagonist and antianexiety activities and they showed high activity compared with procaine amide, lidocaine, diazepam and buspirone as positive controls. The detailed synthesis, spectroscopic data, LD...

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPAR (Buspirone Hydrochloride) Tablet [Bristol-Myers Squibb Company]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 12 Oct 2010 05:00:00 +0100

Updated Date: Oct 12, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [UDL Laboratories, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 07 Oct 2010 05:00:00 +0100

Updated Date: Oct 7, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [NCS HealthCare Of KY, Inc Dba Vangard Labs]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 01 Oct 2010 05:00:00 +0100

Updated Date: Oct 1, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HCL (Buspirone Hydrochloride) Tablet [Rebel Distributors Corp.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 21 Sep 2010 05:00:00 +0100

Updated Date: Sep 21, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Evaluation of Central Serotonin Sensitivity in Breast Cancer Survivors with Cancer-Related Fatigue Syndrome

Journal of Pain and Symptom Management — Tue, 14 Sep 2010 00:00:00 +0100

Conclusions: This study has demonstrated the utility and acceptability of buspirone as a probe of central serotonin sensitivity in this population. No evidence was found for alterations in central serotonin sensitivity in patients with CRFS. Conclusions are tentative, however, because poor recruitment resulted in a small sample and an underpowered comparison. (Source: Journal of Pain and Symptom Management)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Attenuation of fear-like response by escitalopram treatment after electrical stimulation of the midbrain dorsolateral periaqueductal gray.

Experimental Neurology — Thu, 09 Sep 2010 23:00:00 +0100

Authors: Lim LW, Blokland A, Tan S, Vlamings R, Sesia T, Mohammadi MA, Visser-Vandewalle V, Steinbusch HW, Schruers K, Temel Y Electrical stimulation of the dorsolateral periaqueductal gray (dlPAG) has frequently been shown to induce escape and freezing/decreased locomotion responses which mimic panic- and fear-like behaviour. In the present study we tested whether such spontaneous fear-like behaviour could be observed in an open field test 12 h after dlPAG stimulation. Further, we tested whether this fear-like behaviour could be attenuated by acute or chronic administration of buspirone and escitalopram. Our data demonstrate for the first time that animals showed fear-like behaviour 12 h after dlPAG stimulation, which may possibly reflect panic disorder with anticipatory anxiety/agora...

BUSPIRONE HYDROCHLORIDEtablet [IVAX Pharmaceuticals, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 Aug 2010 05:00:00 +0100

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [TEVA Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 27 Aug 2010 05:00:00 +0100

Updated Date: Aug 27, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDEtablet [STAT RX USA LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 16 Aug 2010 05:00:00 +0100

Updated Date: Aug 16, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Primary Care Companion to the Journal of Clinical Psychiatry — Fri, 13 Aug 2010 05:30:03 +0100

CONCLUSION: While the development of novel treatments evolves, current management approaches can focus on improving identification and defining optimal use of available therapies for GAD. PMID: 20694114 [PubMed - in process] (Source: Primary Care Companion to the Journal of Clinical Psychiatry)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Clinical observation of anxiety after earthquake by acupuncture and hydro-acupuncture

Journal of Acupuncture and Tuina Science — Sat, 17 Jul 2010 21:13:19 +0100

摘要目的观察针刺配合水针治疗焦虑症的临床疗效. 方法针刺董氏奇穴上三皇为主治疗焦虑症 186 例, 与单纯西药丁螺环酮 (buspirone)治疗的 139 例作疗效对比观察. 结果治疗组总有效率为 91.4%, 对照组为 93.5%, 两组患者汉密尔顿焦虑量表(hamilto...

Treatment of Irritability in Huntington’s Disease

Current Treatment Options in Neurology — Fri, 09 Jul 2010 06:32:39 +0100

Opinion statement Irritability is a common neuropsychiatric feature of Huntington’s disease (HD), with prevalences varying from 38% to 73%. Similar prevalences of irritability are reported in other neurodegenerative disorders and traumatic brain injury, especially when the frontal lobe is involved. Before therapeutic interventions are initiated, the clinician should analyze the severity and frequency of the irritable behavior. By examining irritability in a broader spectrum, a tailor-made treatment can be provided. In general, I recommend as a first step a selective serotonin reuptake inhibitor (SSRI), such as sertraline, or the mood stabilizer valproate; they both have a mild side effect profile. Next, if the result is insufficient, I advise a switch between these t...

BUSPIRONE HYDROCHLORIDEtablet [Par Pharmaceutical Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Tue, 06 Jul 2010 05:00:00 +0100

Updated Date: Jul 6, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Parkinson's transplant clues

NHS News Feed — Thu, 01 Jul 2010 11:00:00 +0100

Conclusion This interesting research was only conducted on two patients but has important implications for the treatment of this devastating disease. It is important to take into account a few features of the research that affect how rapidly the technique might be approved for use again. Few patients who have had neural transplants in the UK could be studied. Of the five patients who recieved transplants in the UK, two had died and one was bedridden and unable to participate in the research. More patients are needed if longer-term effects, adverse events and safety of any revised technique are to be tested in new trails. The drug tested, buspirone, was given by injection and lasted about three to four hours. This may limit the ability to use this therapy in routine treatment after a ...

The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats

Addiction Biology — Tue, 22 Jun 2010 23:00:00 +0100

We have recently reported that the metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates acquisition of conditioned place preference (CPP) induced by heroin and ketamine. The present study investigated to what extent this effect of MPEP can be generalized to other classes of drugs, such as the stimulants nicotine and cocaine, and to drugs that produce CPP in the rat despite a lack of abuse potential in humans, such as buspirone and clonidine. Adult male Sprague Dawley rats were subjected to a standard unbiased CPP protocol (six conditioning sessions lasting 20 minutes for nicotine and 40 minutes for the other compounds). Rats were conditioned with either nicotine (0.05[ndash]0.2 mg/kg, subcutaneously), cocaine [1[ndash]10 mg/kg, intraperitoneal...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 21 Jun 2010 05:00:00 +0100

Updated Date: Jun 21, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

buspirone, Buspar

MedicineNet Medications General — Mon, 14 Jun 2010 07:00:00 +0100

Title: buspirone, BusparCategory: MedicationsCreated: 12/31/1997Last Editorial Review: 6/14/2010 (Source: MedicineNet Medications General)

Venlafaxine: Nocturnal bruxism, treated with buspirone: case report

Reactions — Mon, 07 Jun 2010 13:08:52 +0100

(Source: Reactions)

Buspirone Versus Methylphenidate in the Treatment of Attention Deficit Hyperactivity Disorder: A Double-Blind and Randomized Trial.

Child Psychiatry and Human Development — Tue, 01 Jun 2010 23:00:00 +0100

Authors: Davari-Ashtiani R, Eslami Shahrbabaki M, Razjouyan K, Amini H, Mazhabdar H The efficacy and side effects of buspirone compared with methylphenidate (MPH) in the treatment of children with attention-deficit/hyperactivity disorder (ADHD). A total of 34 children with ADHD as defined by DSM-IV-TR were randomized to buspirone or methylphenidate dosed on weight-adjusted basis at buspirone (0.5 mg/kg/day) and methylphenidate (0.3-1 mg/kg/day) for a 6-week double-blind clinical trial. The principle measures of outcome were the teacher and parent ADHD Rating Scale. The side effects were assessed by the special side effect checklist of each drug. In both groups, the scores of teacher and parent ADHD Rating Scale significantly declined on the 6th week as compared to baseline (p = 0.001)....

Enhanced Bioavailability of Buspirone From Reservoir-Based Transdermal Therapeutic System, Optimization of Formulation Employing Box-Behnken Statistical Design.

AAPS PharmSciTech — Tue, 01 Jun 2010 23:00:00 +0100

Authors: Gannu R, Palem CR, Yamsani SK, Yamsani VV, Yamsani MR The purpose of the present study was to develop and optimize reservoir-based transdermal therapeutic system (TTS) for buspirone (BUSP), a low bioavailable drug. A three-factor, three-level Box-Behnken design was employed to optimize the TTS. Hydroxypropyl methylcellulose, D: -limonene and propylene glycol were varied as independent variables; cumulative amount permeated across rat abdominal skin in 24 h, flux and lag time were selected as dependent variables. Mathematical equations and response surface plots were used to relate the dependent and independent variables. The statistical validity of polynomials was established, and optimized formulation factors were selected by feasibility and grid search. Validation of the opt...

Chronic buspirone treatment decreases 5-HT(2A) receptor densities and the serotonin transporter but increases the density of 5-HT(1B) receptors in the bulbectomized rat model of depression: An autoradiographic study.

Brain Research — Fri, 21 May 2010 23:00:00 +0100

Authors: Sato H, Skelin I, Diksic M The olfactory bulbectomized (OBX) rat model is an animal model of depression. The deregulation of the serotonergic (5-HT) system is implicated in the pathophysiology of depression. Buspirone is a partial agonist of 5-HT(1A) receptors and is used in the treatment of depression and anxiety. The aim of this study was to assess, in OBX rats and sham operated controls, the effect of chronic buspirone treatment on the densities of 5-HT(2A) and 5-HT(1B) receptors, as well as the 5-HT transporter (5-HTT), which are all important mediators of 5-HT transmission. Male Sprague-Dawley rats (180-240 g) were used. Two weeks following the surgeries, the rats were assigned into the saline or treatment groups, receiving either saline, or 10 or 20 mg/kg day of buspiron...

Medications Acting on the Serotonergic System for the Treatment of Alcohol Dependent Patients.

Current Pharmaceutical Design — Wed, 19 May 2010 23:00:00 +0100

Authors: Kenna GA Research suggests that alcoholics show comparatively lower levels of serotonin (5-HT) than non-alcoholics. Medications aimed at increasing synaptic 5-HT have long been studied as potential treatments for alcoholism. Studies with selective serotonin reuptake inhibitors (SSRI) in a heterogeneous population of non-depressed alcoholics have produced inconsistent results. Further exploration involved whether or not treatment of co-morbid alcoholism and depression was a more practical approach. However, even in the presence of co-occurring depression, antidepressants in general lack the power to demonstrate a significant reduction of alcohol use among alcohol dependent patients with carefully diagnosed major depression. Further statistical analysis has also determined that ...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

BUSPIRONE HYDROCHLORIDEtablet [NCS HealthCare Of KY, Inc Dba Vangard Labs]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 14 May 2010 05:00:00 +0100

Updated Date: May 14, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Dose-effect study of Gelsemium sempervirens in high dilutions on anxiety-related responses in mice

Psychopharmacology — Mon, 19 Apr 2010 05:48:52 +0100

Conclusion The overall pattern of results provides evidence that G. sempervirens acts on the emotional reactivity of mice, and that its anxiolytic-like effects are apparent, with a non-linear relationship, even at high dilutions. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-010-1855-2Authors Paolo Magnani, Università di Verona Dipartimento di Patologia Strada Le Grazie 37134 Verona ItalyAnita Conforti, University of Verona Department of Medicine and Public Health Verona ItalyElisabetta Zanolin, University of Verona Department of Medicine and Public Health Verona ItalyMarta Marzotto, Università di Verona Dipartimento di Patologia Strada Le Grazie 37134 Verona ItalyPaolo Bellavite, Università di Verona Dipartimento di Patologia Strad...

The Brown University Geriatric Psychopharmacology Update — Tue, 13 Apr 2010 13:24:47 +0100

Anticonvulsants, Bipolar Disorder, and Increased Fracture RiskSertraline and Buspirone Found Effective for Treating GAD in ElderlyAnticholinergic Drugs and Adverse Neuropsychiatric EffectsConference Update From AAGP 2010 Annual MeetingPotential Increased CVD Mortality Risk With Clozapine in Older Schizophrenic PatientsCommentary on Anticonvulsants and Fractures StudyMethylphenidate Improves Apathy in Dementia PatientsAmyloid-Beta Reduction With BapineuzumabNew Test for Early AD DetectionMethylphenidate for Catatonia in an Elderly Depressed WomanWarning Letter for Rozerem Promotional Claims (Source: The Brown University Geriatric Psychopharmacology Update)

MedWorm Sponsor Message: Find the best January Sales in the UK.

BUSPIRONE HYDROCHLORIDEtablet [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 08 Apr 2010 05:00:00 +0100

Updated Date: Apr 8, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE (Buspirone Hydrochloride) Tablet [STAT RX USA LLC]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 05 Apr 2010 05:00:00 +0100

Updated Date: Apr 5, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone

Journal of Psychopharmacology — Thu, 01 Apr 2010 10:55:49 +0100

(Source: Journal of Psychopharmacology)

Oral administration of a tri-therapy for central pattern generator activation in paraplegic mice: Proof-of-concept of efficacy.

Biotechnology Journal — Fri, 26 Mar 2010 00:00:00 +0100

Authors: Guertin PA, Ung RV, Rouleau P Spinal cord injury (SCI) is a neurological condition, for which no cure exists, typically leading to an immediate and irreversible loss of sensory and voluntary motor functions accompanied by significant health problems. We conducted proof-of-concept experiments aimed at assessing efficacy upon oral administration of a novel combination therapy for central pattern generator (CPG) activation and corresponding locomotor movement generation in completely paraplegic animals. Co-administration orally (by gavage) of buspirone, levodopa and carbidopa was found to dose-dependently induce episodes of steady weight-bearing stepping in low-thoracic (Th9/10) spinal cord-transected (Tx) mice (with no other form of assistance or training). Robust hindlimb stepp...

BUSPIRONE HYDROCHLORIDEtablet [Dr. Reddy'S Laboratories Ltd]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Mon, 22 Mar 2010 05:00:00 +0100

Updated Date: Mar 22, 2010 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Hormonal responses to the 5-HT1A agonist buspirone in remitted endogenous depressive patients after long-term imipramine treatment

Psychoneuroendocrinology — Fri, 19 Mar 2010 18:03:31 +0100

Summary: Introduction: The serotonin-1A (5-HT1A) receptor subtypes are considered as targets of a variety of antidepressant drugs. Previous studies have suggested different adaptive changes in pre- and post-synaptic 5-HT receptors in the brain after treatment with non-selective tricyclic antidepressants (TCA) and selective 5-HT re-uptake inhibitors (SSRIs). The present study aimed to investigate the adaptive effect of the TCA imipramine on the post-synaptic 5-HT1A receptor function in the hypothalamus.Methods: A longitudinal design was used in 14 patients with major depressive disorder (DSM-IV) with endogenous features (Newcastle Scale) in order to assess the functional status of post-synaptic 5-HT1A receptors before and after successful antidepressant treatment with imipramine. The effect...

Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT(1A) receptors in rats.

Pharmacological Reports — Mon, 01 Mar 2010 00:00:00 +0100

This study aimed to investigate the effect of buspirone, as a partial agonist of 5-HT(1A) receptors, on 6-hydroxydopamine (6-OHDA)-induced catalepsy in male Wistar rats. Catalepsy was induced by unilateral infusion of 6-OH-DA (6 mug/2 mul/rat) into the central region of the substantia nigra pars compacta (SNc) and assayed by the bar-test method 60, 120 and 180 min after drug administration. The results demonstrated that intraperitoneal (ip) injection of buspirone at doses of 5, 7.5 and 10 mg/kg decreased catalepsy compared with the control group. In addition, intra-SNc injection of 8-hydroxy-2-[di-n-propylamino]tetralin (8-OH-DPAT; 10 mug/rat), a 5-HT(1A) receptor agonist, decreased 6-OHDA-induced catalepsy. The effects of buspirone (7.5 mg/kg, ip) and 8-OH-DPAT (10 mug/rat, intra-SNc) wer...

Identification of Molecular Targets Associated With Ethanol Toxicity and Implications in Drug Development.

Current Pharmaceutical Design — Thu, 25 Feb 2010 00:00:00 +0100

In this study, we have examined the molecular targets of ethanol-induced toxicity in humans based on a systematic review of literature data and then discussed current and potential therapeutic targets for alcohol abuse and dependence. Using human samples with ethanol exposure, microarray analyses of gene expression have shown that numerous genes are up- and/or down-regulated by alcohol exposure. The ethanol-responsive genes mainly encode functional proteins such as proteins involved in nucleic acid binding, transcription factors, selected regulatory molecules, and receptors. These genes are also correlated with important biological pathways, such as angiogenesis, integrin signalling pathway, inflammation, wnt signaling pathway, platelet-derived growth factor signaling pathway, p53 pathway,...

Psychopharmacological Neuroprotection in Neurodegenerative Disease: Assessing the Preclinical Data [SPECIAL ARTICLES]

J Neuropsychiatry Clin Neurosci — Tue, 16 Feb 2010 20:34:00 +0100

This manuscript reviews the preclinical in vitro, ex vivo, and nonhuman in vivo effects of psychopharmacological agents in clinical use on cell physiology with a view toward identifying agents with neuroprotective properties in neurodegenerative disease. These agents are routinely used in the symptomatic treatment of neurodegenerative disease. Each agent is reviewed in terms of its effects on pathogenic proteins, proteasomal function, mitochondrial viability, mitochondrial function and metabolism, mitochondrial permeability transition pore development, cellular viability, and apoptosis. Effects on the metabolism of the neurodegenerative disease pathogenic proteins alpha-synuclein, beta-amyloid, and tau, including tau phosphorylation, are particularly addressed, with application to Alzheime...

Fluoxetine: Sleep bruxism successfully treated with buspirone: case report

Reactions — Wed, 10 Feb 2010 14:08:42 +0100

(Source: Reactions)

MedWorm Sponsor Message: Find the best January Sales in the UK.

Neuropharmacology of Buspirone

Psychopathology — Thu, 04 Feb 2010 23:00:00 +0100

Psychopathology 1984;17:6978 (DOI:10.1159/000284133) (Source: Psychopathology)

Clinical Studies of Buspirone

Psychopathology — Thu, 04 Feb 2010 23:00:00 +0100

Psychopathology 1984;17:6168 (DOI:10.1159/000284132) (Source: Psychopathology)

Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder

Psychiatry and Clinical Neurosciences — Mon, 01 Feb 2010 00:00:00 +0100

Conclusion: Both sertraline and buspirone appear to be efficacious and well tolerated in the treatment of GAD in elderly patients. Further studies with larger sample size, evaluating the effect of medical illness, cognitive impairment, depression, and combined therapy with support and psychotherapy are needed. (Source: Psychiatry and Clinical Neurosciences)

The modified Geller-Seifter test in rats was insensitive to GABA(B) receptor positive modulation or blockade, or 5HT(1A) receptor activation.

Behavioural Brain Research — Fri, 11 Dec 2009 00:00:00 +0100

Authors: Paterson NE, Hanania T Rationale: Both the GABA(B) receptor positive modulator GS39783 and the GABA(B) receptor antagonist CGP46381 exhibit anxiolytic-like properties in animal models. In the present studies, the effects of GS39783 and CGP46381 in the modified Geller-Seifter task were assessed. First, the predictive validity of the task was confirmed by assessing the effects of multiple anxiolytic and non-anxiolytic compounds on punished and unpunished responding. Methods: Rats were trained in the modified Geller-Seifter task. After successful acquisition of the task, chlordiazepoxide, diazepam, MPEP, haloperidol, GS39783, 8-OH-DPAT, alprazolam and CGP46381 were tested consecutively. For each test compound, doses were administered in a randomized, counter-balanced, within-subj...

BUSPIRONE HYDROCHLORIDEtablet [Mylan Pharmaceuticals Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 03 Dec 2009 05:00:00 +0100

Updated Date: Dec 3, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review

Headache: The Journal of Head and Face Pain — Wed, 18 Nov 2009 00:00:00 +0100

(Headache 2009;[bull][bull]:[bull][bull]-[bull][bull]) The US Food and Drug Administration (FDA) have suggested that fatal serotonin syndrome (SS) is possible with selective serotonin reuptake inhibitors (SSRIs) and triptans: this warning affects millions of patients as these drugs are frequently given simultaneously. SS is a complex topic about which there is much misinformation. The misconception that 5-HT1A receptors can cause serious SS is still widely perpetuated, despite quality evidence that it is activation of the 5-HT2A receptor that is required for serious SS. This review considers SS involving serotonin agonists: ergotamine, lysergic acid diethylamide, bromocriptine, and buspirone, as well as triptans, and reviews the experimental foundation underpinning the latest understanding...

Triptans, Serotonin Agonists, and Serotonin Syndrome (Serotonin Toxicity): A Review.

Headache — Tue, 17 Nov 2009 00:00:00 +0100

Authors: Ken Gillman P (Headache 2009;**:**-**) The US Food and Drug Administration (FDA) have suggested that fatal serotonin syndrome (SS) is possible with selective serotonin reuptake inhibitors (SSRIs) and triptans: this warning affects millions of patients as these drugs are frequently given simultaneously. SS is a complex topic about which there is much misinformation. The misconception that 5-HT1A receptors can cause serious SS is still widely perpetuated, despite quality evidence that it is activation of the 5-HT2A receptor that is required for serious SS. This review considers SS involving serotonin agonists: ergotamine, lysergic acid diethylamide, bromocriptine, and buspirone, as well as triptans, and reviews the experimental foundation underpinning the latest understanding of...

Effect of serotonergic system on AVP secretion induced by physical exercise

Neuropeptides — Mon, 16 Nov 2009 00:00:00 +0100

Abstract: The present study was undertaken in order to establish the possible involvement of serotonergic receptors in the control of physical exercise-stimulated vasopressin secretion. Twenty-one healthy men (divided in three groups of seven) underwent bicycle-ergometer tests until exhaustion: exercise control test (n=21), exercise plus ondansetron, selective 5-HT3 antagonist (n=7), exercise plus buspirone, selective 5-HT1A receptor agonist (n=7), exercise plus sumatriptan, selective 5-HT1D receptor agonist (n=7). AVP levels, physiological and biochemical variables were measured and compared during tests. Results showed that exercise-induced AVP rise did not change after the administration of buspirone and sumatriptan. In contrast, the administration of ondansetron significantly reduced p...

BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Thu, 12 Nov 2009 05:00:00 +0100

Updated Date: Nov 12, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

BUSPIRONE HYDROCHLORIDE (Buspirone) Tablet [Physicians Total Care, Inc.]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Fri, 30 Oct 2009 05:00:00 +0100

Updated Date: Oct 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

MedWorm Sponsor Message: Find the best January Sales in the UK.

Oxidative stress in rat hippocampus caused by pilocarpine-induced seizures is reversed by buspirone.

Brain Research Bulletin — Wed, 30 Sep 2009 23:00:00 +0100

Authors: Freitas RL, Santos IM, Souza GF, Saldanha GB, Freitas RM Temporal lobe epilepsy is the most common form of epilepsy in humans. Oxidative stress is a mechanism of cell death induced by seizures. Buspirone presents anxyolitic and antidepressant effects due to their ability to stimulate 5-HT(1A) receptor. We studied the buspirone effects on oxidative stress in rat hippocampus after seizures and status epilepticus (SE) induced by pilocarpine. In pilocarpine group there was a significant increase in lipid peroxidation and nitrite levels. However, no alteration was observed in superoxide dismutase and catalase activities. Buspirone pretreatment produces significantly reduction the lipid peroxidation level (60%) and nitrite content (44%) as well as increased the superoxide dismutase ...

BUSPIRONE HYDROCHLORIDEtablet [Major Pharmaceuticals]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 30 Sep 2009 05:00:00 +0100

Updated Date: Sep 30, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

A placebo-controlled trial of buspirone for the treatment of marijuana dependence

Drug and Alcohol Dependence — Mon, 14 Sep 2009 18:19:29 +0100

Abstract: The present study investigated the potential efficacy of buspirone for treating marijuana dependence. Participants received either buspirone (maximum 60mg/day) (n=23) or matching placebo (n=27) for 12 weeks, each in conjunction with motivational interviewing. In the modified intention-to-treat analysis, the percentage of negative UDS results in the buspirone-treatment group was 18 percentage points higher than the placebo-treatment group (95% CI: −2% to 37%, p=0.071). On self-report, participants receiving buspirone reported not using marijuana 45.2% of days and participants receiving placebo reported not using 51.4% of days (p=0.55). An analysis of participants that completed the 12-week trial showed a significant difference in the percentage negative UDS (95% CI: 7–63%, p=0...

Low-Dose Buspirone, Melatonin and Low-Dose Bupropion Added to Mood Stabilizers for Severe Treatment-Resistant Bipolar Depression

Karger Publishers — Mon, 07 Sep 2009 23:00:00 +0100

Psychother Psychosom 2009;78:391-393 (DOI:10.1159/000235985) (Source: Karger Publishers)

Relations between open-field, elevated plus-maze, and emergence tests in C57BL/6J and BALB/c mice injected with GABA- and 5HT-anxiolytic agents

Fundamental and Clinical Pharmacology — Thu, 03 Sep 2009 23:00:00 +0100

Two 5HT1A receptor agonists and chlordiazepoxide were examined in open-field, elevated plus maze, and emergence tests. At doses with no effect in the open-field, chlordiazepoxide increased open and open/total arm visits as well as open arm duration in the elevated plus maze, whereas 5HT1A receptor agonists showed an anxiolytic response on a single measure. The anxiolytic action of chlordiazepoxide was limited to the less active BALB/c strain. Unlike the 5HT1A receptor agonists, chlordiazepoxide was also anxiolytic in the emergence test, once again only in BALB/c and not C57BL/6J mice. Significant correlations were found between emergence latencies and specific indicators of anxiety in the elevated plus-maze in chlordiazepoxide-treated but not in mice treated with buspirone and 8-OH-DPAT. T...

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Fluoxetine-induced sleep bruxism in an adolescent treated with buspirone: a case report

Special Care in Dentistry — Mon, 24 Aug 2009 23:00:00 +0100

This article reports on a case history of an adolescent with fluoxetine-induced bruxism that was successfully treated with buspirone. As SSRI use is on the rise for treating childhood psychiatric disorders, this case report highlights the importance of recognizing SSRI-induced bruxism and the possible related adverse dental side effects. Furthermore, this report supports the efficacy of a treatment strategy in adolescents, which has previously been reported only for adult patients. (Source: Special Care in Dentistry)

BUSPIRONE HYDROCHLORIDEtablet [TEVA Pharmaceuticals USA Inc]

DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) — Wed, 19 Aug 2009 05:00:00 +0100

Updated Date: Aug 19, 2009 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Two-injection workflow for a liquid chromatography/LTQ-Orbitrap system to complete in vivo biotransformation characterization: demonstration with buspirone metabolite identification.

Rapid Communications in Mass Spectrometry : RCM — Wed, 12 Aug 2009 23:00:00 +0100

Authors: Li AC, Ding J, Jiang X, Denissen J The relatively high background matrix in in vivo samples typically poses difficulties in drug metabolite identification, and causes repeated analytical runs on unit resolution liquid chromatography/mass spectrometry (LC/MS) systems before the completion of biotransformation characterization. Ballpark parameter settings for the LTQ-Orbitrap are reported herein that enable complete in vivo metabolite identification within two HPLC/MS injections on the hybrid LTQ-Orbitrap data collection system. By setting the FT survey full scan at 60K resolution to trigger five dependent LTQ MS(2) scans, and proper parameters of Repeat Duration, Exclusion Duration and Repeat Count for the first run (exploratory), the Orbitrap achieved the optimal parallel data...

Defeating Normal Thermoregulatory Defenses. Induction of Therapeutic Hypothermia.

Stroke — Wed, 12 Aug 2009 23:00:00 +0100

Authors: Sessler DI Therapeutic hypothermia may be useful in various circumstances including stroke. However, core body temperature is normally tightly regulated. Even mild hypothermia in conscious subjects thus provokes vigorous thermoregulatory defenses which are potentially harmful in fragile patients. Furthermore, thermoregulatory responses are effective, which reduces the rate at which hypothermia can be induced. Drugs are thus often given to blunt normal thermoregulatory defenses. General anesthetics profoundly impair thermoregulatory control, but prolonged general anesthesia is rarely practical or appropriate. A variety of other drugs have therefore been evaluated. Most opioids only slightly impair thermoregulatory defenses, but meperidine is considerably more effective than equ...

Intraneuronal β-Amyloid Accumulation in the Amygdala Enhances Fear and Anxiety in Alzheimer's Disease Transgenic Mice

Biological Psychiatry — Mon, 10 Aug 2009 00:00:00 +0100

Conclusions: We propose a deleterious role of intraneuronal Aβ on amygdala-dependent emotional responses by affecting the extracellular signal-regulated kinase/mitogen-activated protein kinase (ERK/MAPK) signaling pathway. (Source: Biological Psychiatry)

MedWorm Sponsor Message: Find the best January Sales in the UK.

5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response

European Archives of Psychiatry and Clinical Neuroscience — Thu, 30 Jul 2009 10:11:22 +0100

We examined whether the sensitivity of the 5HT1A receptor, as measured by the difference in salivary cortisol levels immediately before and 90 min following the administration of a single dose of the 5HT1A-selective agonist buspirone, predicted treatment outcome following an 8-week, fixed-dose, open trial of the SSRI escitalopram in 17 outpatients with MDD. Change in cortisol levels before and 90 min after the administration of buspirone were not found to predict treatment outcome, whether defined as clinical response (50% or greater reduction in symptom severity), or remission of symptoms. In conclusion, in the present study, we did not find that the change in salivary cortisol levels following the administration of a 5HT1A-selective agonist predicted treatment outcome fol...

Unlikely Treatment Identified By BrainCells Neurogenesis Platform Improved Clinical Outcomes In Patients Suffering From Depression

Health News from Medical News Today — Tue, 28 Jul 2009 08:00:00 +0100

BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). (Source: Health News from Medical News Today)

Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT1A receptor agonist

Human Psychopharmacology: Clinical and Experimental — Mon, 27 Jul 2009 23:00:00 +0100

To assess effects of a semi-acute administration of buspirone in comparison to a placebo on cognitive function and negative symptoms in patients with schizophrenia and schizoaffective disorder.In a 6-week, double-blind, placebo-controlled, independent groups study 18 subjects (14 males, four females) received in random order either placebo or buspirone (15-30 mg/day). A neuropsychological assessment using the Hopkins verbal learning test (HVLT) simple reaction time (SRT), choice reaction time (CRT), n-back spatial working memory task and the stroop colour and word test was performed at baseline and final visit. Symptom rating scales were administered at testing weeks 0, 2, 4 and 6.Repeated measures ANOVA was used to examine changes in performance on tests over time. There were no statistic...

Unlikely Treatment Identified By BrainCells Neurogenesis Platform Improved Clinical Outcomes In Patients Suffering From Depression

Pharmaceutical Online News — Mon, 27 Jul 2009 06:08:00 +0100

BrainCells Inc., a company leading the scientific research of neurogenesis using its proprietary platform technology to identify novel pathways for the treatment of central nervous system (CNS) diseases, announced recently results from the first clinical proof-of-concept study of BCI-952, a combination of low dose buspirone and melatonin, for the treatment of major depressive disorder (MDD). (Source: Pharmaceutical Online News)

Magnitude of potentially inappropriate prescribing in Germany among older patients with generalized anxiety disorder

BMC Geriatrics — Sun, 26 Jul 2009 23:00:00 +0100

Conclusions: GPs in Germany often prescribe medications that have been designated as potentially inappropriate to their elderly patients with GAD--especially those with comorbid depressive disorders. Further research is needed to ascertain whether there are specific subgoups of elderly patients with GAD for whom the benefits of these medications outweigh their risks. (Source: BMC Geriatrics)

MedWorm Sponsor Message: Please support the Doctors In Chains campaign for the medics tortured and sentenced for up to 15 years in Bahrain. #FreeDoctors

Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat

Psychopharmacology — Sat, 25 Jul 2009 04:18:57 +0100

Conclusions These studies implicate the role of 5-HT7, 5-HT2C, and 5-HT1A receptors in the improvement of cognitive dysfunction of relevance to schizophrenia. Content Type Journal ArticleCategory Original InvestigationDOI 10.1007/s00213-009-1618-0Authors Samantha L. McLean, University of Bradford Bradford School of Pharmacy Bradford West Yorkshire BD7 1DP UKMarie L. Woolley, GlaxoSmithKline New Frontiers Science Park, Third Avenue Harlow Essex CM19 5AW UKDave Thomas, GlaxoSmithKline New Frontiers Science Park, Third Avenue Harlow Essex CM19 5AW UKJoanna C. Neill, University of Bradford Bradford School of Pharmacy Bradford West Yorkshire BD7 1DP UK Journal PsychopharmacologyOnline ISSN 1432-2072Print ISSN 0033-3158 (Source: Psychopharmacology)

Development of high performance liquid chromatography method for buspirone in rabbit serum: Application to pharmacokinetic study.

Analytica Chimica Acta — Wed, 15 Jul 2009 17:50:12 +0100

Authors: Gannu R, Yamsani SK, Palem CR, Yamsani VV, Kotagiri H, Yamsani MR A simple and sensitive high performance liquid chromatographic (HPLC) method for quantification of buspirone (BUSP) in rabbit serum was developed and validated. BUSP and internal standard (IS), diltiazem hydrochloride were extracted into dichloromethane and separated using an isocratic mobile phase, on a Kromasil C(8) column. The eluent was monitored by UV detector at 235 nm and at a flow rate of 1.0 mL min(-1). The linearity range of proposed method was 1-3000 ng mL(-1). The intra-day and inter-day coefficient of variation and percent error values of the assay method were less than 15% and mean recovery was more than 97 and 96% for BUSP and IS, respectively. The method was found to be precise, accurate, and spe...

Reduction of the number of new cells reaching olfactory bulbs impairs olfactory perception in the adult opossum.

Acta Neurobiologiae Experimentalis — Tue, 14 Jul 2009 20:46:03 +0100

In conclusion, lower numbers of new neurons in the opossums OB correlated with their worse behavioral performance in a test based on olfactory perception. PMID: 19593331 [PubMed - in process] (Source: Acta Neurobiologiae Experimentalis)

Buspar (Buspirone) - updated on RxList

RxList - New and Updated Drug Monographs — Mon, 06 Jul 2009 07:00:00 +0100

Buspar (Buspirone) drug description - FDA approved labeling for prescription drugs and medications at RxList (Source: RxList - New and Updated Drug Monographs)